Identification Of Telomere-specific Recombination Pathways
Funder
National Health and Medical Research Council
Funding Amount
$540,075.00
Summary
Human cells stop to grow when the natural ends of chromosomes become too short. One way of how cancer cells evade this growth arrest is by using a copy-mechanism to extend short chromosome ends. Ironically, this copy mechanism is usually used by cells to keep the structure of chromosomes intact in order to prevent mutations that cause cancer. Here we will study a novel protein that contributes to the copy mechanism at short chromosome ends, but not as much in normal mutation prevention.
Feasibility Of Implementing Precision Medicine For The Treatment Of Metastatic Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Melanoma is the most aggressive form of skin cancer, accounting for 75% of skin cancer deaths in Australia. When it progresses to stage IV disease, patient prognosis is poor, with less than 10% of cases surviving to 5 years. The goal of this project is to determine whether drugs currently used to treat different diseases could also be used to treat melanoma patients and improve their survival, particularly those that do not respond in current clinical trials.
The Role And Underlying Mechanisms Of Constitutional Epigenetic Silencing In Cancer Predisposition
Funder
National Health and Medical Research Council
Funding Amount
$218,617.00
Summary
Familial and young onset bowel and uterine cancer are usually caused by the inheritance of spelling mistakes in the genetic code within a set of cancer-protection genes. Recently, some patients were identified with their gene switched off by paralysing chemicals instead. This study aims to identify additional cancer cases with gene paralysis, determine if this arises in the presence or absence of a genetic change in front of the gene, and how gene paralysis is transmitted to the next generation.
Identification And Characterisation Of A Novel Genetic Signature At The 5p15 Region Associated With Risk Of Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$610,974.00
Summary
We have recently replicated the genetic association of a region (5p15) with the risk of prostate cancer in Australian men. We now seek to identify the precise genetic variant behind this association, and the functional role of these novel gene/s and variants in disease pathology. Our results will provide a foundation for the development of sensitive and readily applicable lab-based screening tools to be used clinically and will also provide impetus for drug-targeted research by furthering our un ....We have recently replicated the genetic association of a region (5p15) with the risk of prostate cancer in Australian men. We now seek to identify the precise genetic variant behind this association, and the functional role of these novel gene/s and variants in disease pathology. Our results will provide a foundation for the development of sensitive and readily applicable lab-based screening tools to be used clinically and will also provide impetus for drug-targeted research by furthering our understanding on this multifactorial disease.Read moreRead less
I am a molecular geneticist with a special interest in molecular pathology determining the inherited and somatic genetic events that predispose to, and advance cancer development. Much of this work has immediate translatability to clinical genetics practi
Tailoring Targeted Therapy To DNA Repair-defective High-Grade Serous Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$802,247.00
Summary
Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and should be susceptible to new PARP inhibitor therapy, yet not all those respond. By developing a new model of studying human ovarian cancers in mice, we can discover markers to predict which ovarian cancers will respond best to these exciting new treatments.
Molecular Epidemiology Of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core
Funder
National Health and Medical Research Council
Funding Amount
$883,244.00
Summary
Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 new cases diagnosed and 750 deaths each year. There is an urgent need to better understand the molecular, epidemiological and genetic characteristics of epithelial ovarian cancer and how these influence response to treatment and clinical outcome. Ovarian cancer is a histologically and clinically diverse disease and the variability in clinical outcome in ovaria ....Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 new cases diagnosed and 750 deaths each year. There is an urgent need to better understand the molecular, epidemiological and genetic characteristics of epithelial ovarian cancer and how these influence response to treatment and clinical outcome. Ovarian cancer is a histologically and clinically diverse disease and the variability in clinical outcome in ovarian cancer patients suggests that reliable predictive factors would be of clinical value. However, it is clear that the collection of hundreds of annotated biospecimens is essential if the interaction of genes and environment in the genesis of this disease is to be understood or the molecular features of this disease dissected. Recognizing that this can only be achieved through large-scale collaboration, the Australian Ovarian Cancer Study (AOCS) was established in 2000 by scientists from the Peter MacCallum Cancer Centre, the Queensland Institute for Medical Research, Melbourne University and Westmead Institute for Cancer Research in collaboration with clinicians across Australia. AOCS has recruited 1105 patients to date and this Research Proposal aims to complete the collection of clinical data on all AOCS patients nationally, to validate the use of microarray gene expression profiles to predict clinical outcome and to find genetic variants that may determine clinical outcome in individual patients. The creation of AOCS has provided a unique oportunity to collect one of the finest ovarian cancer biological sample sets in the world. We believe that this internationally significant study will shed light on the basis of response of ovarian cancer to treatment and provide an ongoing resource for research into the causes of ovarian cancer, and studies on the response to treatment.Read moreRead less
Australian Prostate Cancer Collaboration (APCC) Bio-Resource
Funder
National Health and Medical Research Council
Funding Amount
$2,310,000.00
Summary
The Australian Prostate Cancer Collaboration (APCC), supported by the Commonwealth Bank, Prostate Cancer Foundation of Australia and Andrology Australia, has been developing an Australia-wide network of prostate tissue banks and associated clinical databases for the past 3 years. The concept of this innovative project is to establish “nodes” or branches of the tissue bank in each State where tissues are collected and to coordinate the use of this material from a central committee or “head office ....The Australian Prostate Cancer Collaboration (APCC), supported by the Commonwealth Bank, Prostate Cancer Foundation of Australia and Andrology Australia, has been developing an Australia-wide network of prostate tissue banks and associated clinical databases for the past 3 years. The concept of this innovative project is to establish “nodes” or branches of the tissue bank in each State where tissues are collected and to coordinate the use of this material from a central committee or “head office”. A website has been established (www.apccbioresource.org.au) that is the national face of this ‘virtual’ national tissue bank and 7 State-based tissue bank consortiums are participating in this venture. The goal of this ‘virtual bank’ or network is to further enhance the national research effort by facilitating greater collaboration nationally and providing better access to, and optimal utilisation of, the clinical material available to facilitate improvements in prostate cancer management. Operational support for the nodes is critical for the success of a national Bio-Resource.Read moreRead less
The Downstream Targets Of Patched/Hedgehog Signalling.
Funder
National Health and Medical Research Council
Funding Amount
$423,055.00
Summary
The patched-hedgehog gene pathway is disturbed in common human cancer, including basal cell carcinoma of the skin, medulloblastoma, rhabdomyosarcoma and ovarian fibroma. This application proposes to look at the genes turned off and on by the patched gene. By identifying these genes and examining their function we will identify the exact genetic disturbance which results in a large proportion of common human cancer. Once we find these genes this opens up the possibilities of designing drugs which ....The patched-hedgehog gene pathway is disturbed in common human cancer, including basal cell carcinoma of the skin, medulloblastoma, rhabdomyosarcoma and ovarian fibroma. This application proposes to look at the genes turned off and on by the patched gene. By identifying these genes and examining their function we will identify the exact genetic disturbance which results in a large proportion of common human cancer. Once we find these genes this opens up the possibilities of designing drugs which specifically block the action of the geneticdefect and thereby treating the tumours.Read moreRead less